Search

Search Constraints

You searched for: Author/Creator Rolf, Michael G.

Search Results

2. In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Issue 5 (4th September 2015)

3. Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective. Issue 2 (24th September 2020)

4. Time for a Fully Integrated Nonclinical–Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective. Issue 2 (24th September 2020)